Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Kyowa Kirin Ord Shs KYKOF

Alternate Symbol(s):  KYKOY

Healthcare Biotechnology
Kyowa Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of medical drugs. The Company operates in Pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has drug discovery technologies in antibody therapeutics and hematopoietic stem cell gene therapy. Its... see more

Current News (PINL:KYKOF)

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

PR Newswire June 7, 2021

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021

PR Newswire May 19, 2021

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress

PR Newswire May 12, 2021

Kyowa Kirin North America Announces Key Executive Appointments in R&D and Medical Affairs As Late-Stage Assets Move Toward Key Milestones

PR Newswire May 4, 2021

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan

PR Newswire April 14, 2021

MEI Pharma and Kyowa Kirin Announce Completion of Patient Enrollment in Follicular Lymphoma Primary Efficacy Population of Global Phase 2 TIDAL Study Intended to Support Potential Accelerated Approval Application from U.S. Food and Drug Administration (FDA)

PR Newswire April 13, 2021

Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory

PR Newswire March 31, 2021

New Data from MAVORIC Trial Sheds Light on Key Characteristics of Long-term POTELIGEO® (mogamulizumab-kpkc) Responders with Specific Subtypes of Cutaneous T-cell Lymphoma

PR Newswire December 6, 2020

Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020

PR Newswire October 22, 2020
View More News ››

Opinion & Analysis (PINL:KYKOF)

No current opinion is available.
View More Opinion ››

Bullboard Posts (PINL:KYKOF)

Be the first to post on this bullboard.

Fineqia International Inc.

Fineqia International Inc.

Publicly listed in Canada (CSE: FNQ) with quoted symbols on Nasdaq (OTC: FNQQF) and the Frankfurt Stock Exchange (Frankfurt ...
View More »